No Picture
Trading Ideas

UPDATE 1-BeiGene drug wins U.S. FDA approval for rare form of lymphoma

The U.S. Food and Drug Administration on Thursday approved BeiGene Ltd’s lymphoma treatment, validating the China-based drugmaker’s strategy of largely using data from trials held outside the United States to file for approval. The company tested the treatment, Brukinsa, in 118 patients with mantle cell lymphoma enrolled in two studies. About three-quarters were Asian, 21% Caucasian, and between 10% to 15% were from the United States, BeiGene said. …read more […]

No Picture
Trading Ideas

Fed chair Powell warns the U.S. debt pile could hamper fiscal policy

The U.S. budget deficit jumped 34% in October compared to last year, and it’s on pace to top $1 trillion. Federal reserve chair Jerome Powell testifying for the second day on the Hill, warning that the ballooning debt could hamper fiscal policy during economic downturn.. but he said the day of reckoning is still further out. Dan Deming, KKM Financial’s Managing Director joins Yahoo Finance’s Akiko Fujita on The Ticker. …read more […]

No Picture
Trading Ideas

Explaining a LEAPS Play on Freeport-McMoRan

I love trading long-term equity anticipation securities (LEAPS)…
LEAPS are long-term options that have at least one year left before expiration. Since they are more expensive than short-term options (because of the extra time value), many people avoid them.
However, as a fundamental tactician, my goal is not always short-term gains…
Even though most of my trades, LEAPS included, are held for a very short time period.
Confused?
Let me explain…
Because LEAPS have a lot of time on them, a short-term move in underlying shares is magnified in a LEAPS option.
Think about it…
The options pricing model has several components, and a change in any one …read more […]

No Picture
Trading Ideas

Cisco tumbles on lackluster outlook

Cisco shares tumbled after the tech conglomerate provided disappointing guidance for it’s fiscal second-quarter. Yahoo Finance’s Dan Howley joins Akiko Fujita on The Ticker to discuss why the stock is down despite earnings beating Wall Street’s estimates. …read more […]

No Picture
Trading Ideas

Canopy Growth CEO on path to profitability amid disappointing earnings results

Canopy Growth’s shares are plummeting after the cannabis company released its fiscal second quarter earnings report. Canopy Growth CEO Mark Zekulin joins Yahoo Finance’s Zack Guzman and Kristin Myers to discuss the company’s earnings Q2 results and product outlook for 2020. …read more […]